Superworth

908 Devices price to sales ratio MASS

Market value divided by revenue over the last twelve months, since 2022.

Today, Nov 2, 2026
6.9×
5-year median
4.7×
Against its 5-year history
81st
percentile: 0 is its lowest day, 100 its highest
5-year range
1.3× to 17.5×
Peer median
3.8×

908 Devices' price to sales ratio is 6.9× as of Nov 2, 2026.

That is above its 5-year median of 4.7×, higher than on 81% of days in the last 5 years.

Over that time it ranged from 1.3× in Dec 2024 to 17.5× in Aug 2022.

The median for 3 diagnostics and research stocks of a similar size is 3.8×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far6.9×3.2×8.6×
20253.4×1.4×5.4×
20241.4×1.3×5.8×
20237.6×3.4×7.6×
20224.7×4.5×17.5×

Against its peers

Companies in Medical - Diagnostics & Research nearest 908 Devices' size, closest first, today.

CompanyPrice to sales ratio
MASS908 Devices6.9×
NRCNRC Health3.8×
ICCCImmucell3.1×
VCYTVeracyte7.0×
Peer median3.8×

Where 908 Devices ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on 908 Devices

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.